health
IntraBio Announces U.S. FDA Approval of AQNEURSA® (levacetylleucine) for Ataxia-Telangiectasia
AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc., a leader in the discovery, development, and commercialization of novel therapies for rare and common neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved AQNEURSA® (levacetylleucine) for the treatment of ataxia in adult and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg. AQNEURSA is the first and only drug approved for the treatment of A-T anywhere in the world. In the United
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Amesite Announces New Sales Win Under NurseMagic® Minimum Enterprise Pricing Model
Globenewswire_fr
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Globenewswire_fr
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Globenewswire_fr
Adventure With a Purpose: A Race Against Blindness Unveils Adventure Package Fundraiser Valued at $350,000
Globenewswire_fr
Re: Management of paracetamol (acetaminophen) toxicity
Bmj